COVID-19 Research

Throughout the last year, we have amplified sublingual immunotherapy as a safe way to continue allergy treatment while remaining socially distant and freeing up space in practices for more urgent needs. Now, there’s research to back it. We wanted to share some of the key articles that support sublingual immunotherapy during COVID-19.

Coronavirus disease 2019 and allergen immunotherapy

Theoretical benefits invite to adjustments in practice recommendations
Larenas-Linnemann states in the Annals of Allergy & Immunology, “We argue in favor of starting AIT, preferably sublingual immunotherapy, or in clinics where social distancing can be practiced, subcutaneous immunotherapy can be an option.” (Sept 2020) Read the research →


Sublingual immunotherapy in the United States:
history and current relevance in the time of COVID‐19

In the International Forum of Allergy & Rhinology, Lin concludes,”…the home administration of sublingual immunotherapy highlights sublingual immunotherapy as a safe option, with decreased risk for exposure to COVID-19 when compared to injection immunotherapy.” (Oct 2020) Read the research →


Allergen immunotherapy in the current COVID-19 pandemic: A position paper

Klimek discusses different immunotherapy options in a time of COVID-19 and says, “Sublingual immunotherapy offers the possibility of taking the allergen preparation at home… This avoids repeated visits to the practice/allergy department, which is associated with an infection risk.” (May 2020) Read the research →


Need help converting patient’s traditional treatment to sublingual? Contact us today.